ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.
Synonyms: T-cell immunoreceptor with Ig and ITIM domains; V-set and immunoglobulin domain-containing protein 9; V-set and transmembrane domain-containing protein
Storage: 2-8C
Application: Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected TIGIT in Rat Spleen, Mouse Thymus, and Human Spleen tissue lysates.Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected TIGIT in Jurkat and K562 cells. Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected TIGIT in human tonsil tissue sections.Affinity Binding Assay: A representative lot of this antibody bound TIGIT peptide with a KD of value of 3.6 x 10-9 in an affinity binding assay.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany